Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18468385 | 0.83 | CNR2 (0.37) | PIK3CGHPGDKDM4EALDH1A1LMNA | |
| SCHEMBL20464256 | 0.83 | PIK3CG (0.33) | PIK3CGHPGDKDM4EALDH1A1LMNA | |
| SCHEMBL20047553 | 0.83 | PIK3CG (0.33) | PIK3CGHPGDKDM4EALDH1A1LMNA | |
| SCHEMBL12251571 | 0.83 | PIK3CG (0.33) | PIK3CGHPGDKDM4EALDH1A1LMNA | |
| SCHEMBL13230270 | 0.83 | PIK3CG (0.40) | PIK3CGCNR2 | |
| SCHEMBL13618720 | 0.83 | PIK3CG (0.40) | PIK3CG | |
| SCHEMBL17115057 | 0.83 | PIK3CG (0.40) | PIK3CG | |
| SCHEMBL13230271 | 0.83 | PIK3CG (0.47) | PIK3CGHPGD | |
| SCHEMBL13475364 | 0.83 | PIK3CG (0.40) | PIK3CGCNR2 | |
| SCHEMBL22854005 | 0.81 | PIK3CG (0.39) | PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-12037328-B2 | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | PRAMANA PHARMACEUTICALS INC. (CA) | 2024-07-16 | — | — | US | disclosed |
| US-12037328-B2 | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | PRAMANA PHARMACEUTICALS INC. (CA) | 2024-07-16 | — | — | US | disclosed |
| US-20240217935-A1 | METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | LG CHEM, LTD. (KR) | 2024-07-04 | — | — | US | disclosed |
| US-20240217935-A1 | METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | LG CHEM, LTD. (KR) | 2024-07-04 | — | — | US | disclosed |
| US-12024528-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230355647-A1 | Marker for determining anti-cancer effects of mitochondrial oxidative phosphorylation pathway inhibitor | NANJING SHIJIANG MEDICINE TECHNOLOGY CO., LTD (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230355647-A1 | Marker for determining anti-cancer effects of mitochondrial oxidative phosphorylation pathway inhibitor | NANJING SHIJIANG MEDICINE TECHNOLOGY CO., LTD (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080125436-A1 | 4-(5-{(1R)-1-[5-(3-Chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,- 4-triazol-3-yl)-1-methylpyridin-2(1H)-one; transient lower esophageal sphincter relaxations; gastroesophageal reflux disease; pain; anxiety; irritable bowel syndrome; metabotropic glutamate receptor inhibitors; peripherally acting | ASTRAZENECA AB (SE) | 2008-05-29 | — | — | US | disclosed |
| US-20080125436-A1 | 4-(5-{(1R)-1-[5-(3-Chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,- 4-triazol-3-yl)-1-methylpyridin-2(1H)-one; transient lower esophageal sphincter relaxations; gastroesophageal reflux disease; pain; anxiety; irritable bowel syndrome; metabotropic glutamate receptor inhibitors; peripherally acting | ASTRAZENECA AB (SE) | 2008-05-29 | — | — | US | disclosed |
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080051441-A1 | Aryl Sulphonamide Modulators | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259926-A1 | mGluR5 modulators III | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259862-A1 | MGluR5 modulators I | GRM5, GRM1, GRIK5 | PIK3CG 937/4885HPGD 2472/4885KDM4E 1771/4885 |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | CARM1, PRMT1, PRMT3 | PIK3CG 3596/4885HPGD 2834/4885KDM4E 369/4885 |
| US-20230355647-A1 | Marker for determining anti-cancer effects of mitochondrial oxidative phosphorylation pathway inhibitor | SHMT2, UHRF1, SHMT1 | PIK3CG 2006/4885HPGD 466/4885KDM4E 1092/4885 |
| US-20070259926-A1 | mGluR5 modulators III | GRM5, GRM3, GRIK5 | PIK3CG 848/4885HPGD 2761/4885KDM4E 1913/4885 |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | PIK3CG 3409/4885HPGD 172/4885KDM4E 727/4885 |
| US-20080125436-A1 | 4-(5-{(1R)-1-[5-(3-Chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,- 4-triazol-3-yl)-1-methylpyridin-2(1H)-one; transient lower esophageal sphincter relaxations; gastroesophageal reflux disease; pain; anxiety; irritable bowel syndrome; metabotropic glutamate receptor inhibitors; peripherally acting | GLRA1, GRM1, GRM5 | PIK3CG 1948/4885HPGD 1097/4885KDM4E 2178/4885 |
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | CHRNG, CHRNE, CHRNA1 | PIK3CG 2964/4885HPGD 669/4885KDM4E 2378/4885 |
| US-20070259916-A1 | mGluR5 modulators II | GRM5, GRM2, GRIK5 | PIK3CG 929/4885HPGD 2431/4885KDM4E 1827/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | PIK3CG 3000/4885HPGD 4393/4885KDM4E 3087/4885 |
| US-20070259860-A1 | MGluR5 modulators V | GRM5, GRIK5, GRM2 | PIK3CG 791/4885HPGD 2870/4885KDM4E 1403/4885 |
| US-12024528-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | SDHA, SDHB, DPYD | PIK3CG 1586/4885HPGD 264/4885KDM4E 1168/4885 |
| US-12037328-B2 | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | GPR119, GPR3, GPR39 | PIK3CG 2177/4885HPGD 1027/4885KDM4E 2650/4885 |
| US-20080051441-A1 | Aryl Sulphonamide Modulators | CHRM2, CHRM1, CHRNA1 | PIK3CG 4181/4885HPGD 1537/4885KDM4E 2056/4885 |
| US-20240217935-A1 | METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | S1PR4, S1PR1, S1PR3 | PIK3CG 862/4885HPGD 1132/4885KDM4E 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.